The EEF1E1 Knockout K-562 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the K-562 chronic myelogenous leukemia (CML) cell line. This product enables loss-of-function studies of EEF1E1, a critical component of the eukaryotic elongation factor-1 (eEF1) complex and a recognized tumor suppressor. The polyclonal population consists of a heterogeneous pool of gene-edited cells, ensuring robust representation of diverse knockout genotypes while maintaining the biological complexity inherent to the host cell background. This format is particularly suited for experiments where clonal variation is undesirable, such as in tumor heterogeneity modeling or high-throughput drug sensitivity screens.
The parental K-562 cell line was originally established from the pleural effusion of a patient with CML in blast crisis. These cells harbor the Philadelphia chromosome, resulting in expression of the BCR-ABL1 fusion tyrosine kinase, which drives constitutive proliferative and survival signaling. K-562 cells serve as a widely used model for hematopoietic differentiation, leukemia biology, and imatinib sensitivity studies. Their lymphoblastoid morphology and ease of culture make them a versatile platform for interrogating gene function in the context of CML pathogenesis and hematopoietic malignancy.
EEF1E1 encodes a protein that functions as a guanine nucleotide exchange factor for the eEF1A subunit within the eEF1 complex, facilitating the delivery of aminoacyl-tRNA to the A-site of the ribosome during translation elongation. Through its direct physical interactions with eEF1A and the eEF1B subunits (EEF1B2, EEF1D, EEF1G), EEF1E1 promotes efficient protein synthesis. Beyond its canonical role in translation, EEF1E1 acts as a tumor suppressor by mediating DNA damage responses. Under genotoxic stress, EEF1E1 is phosphorylated by ATM and ATR kinases, leading to its nuclear translocation and stabilization of p53. This interaction enhances p53 transcriptional activity, upregulating targets such as CDKN1A and BAX, thereby inducing cell cycle arrest and apoptosis. The pathway is further modulated by upstream regulators including mTORC1 and MYC, and downstream output is measured through p53-dependent gene expression changes.
In the context of K-562 cells, knockout of EEF1E1 disrupts this dual functionality, potentially altering both translational fidelity and DNA damage-induced apoptosis. Given the BCR-ABL1-driven oncogenic signaling in K-562 cells, loss of EEF1E1 may exacerbate leukemogenic phenotypes or modify sensitivity to tyrosine kinase inhibitors like imatinib. This model provides a valuable tool to dissect the crosstalk between the translational machinery and tumor suppressor pathways in CML. Furthermore, because K-562 cells retain some ability to differentiate along erythroid and megakaryocytic lineages, the knockout cells can be utilized to examine EEF1E1??s role in hematopoietic lineage commitment and differentiation under stress conditions.
Researchers can employ this knockout model to perform translation elongation assays using puromycin incorporation, analyze eEF1 complex integrity via co-immunoprecipitation with antibodies against eEF1A or EEF1B subunits, and assess p53 stabilization and transcriptional activity in response to DNA-damaging agents such as etoposide or ionizing radiation. Additional applications include apoptosis assays (e.g., annexin V staining), cell proliferation analyses, and high-throughput drug sensitivity screens with chemotherapeutics or targeted agents. The polyclonal nature of the knockout population is particularly advantageous for investigating heterogeneous drug resistance mechanisms. For further details or customized services, please contact Ascent Research.
